Pharmaceutical Products

We are actively developing treatments for our patients in six important therapeutic areas: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.
  • Immunology
    Our vision is a world free from immune diseases. To achieve this, we will translate internal and external science to deliver products that address immune-mediated diseases.

    We have a strong history of delivering novel medicines for immunological diseases. We continue to build a pipeline of innovative biologic and oral therapies in core disease areas: rheumatoid arthritis, inflammatory bowel diseases and psoriasis. Through our ongoing efforts in discovery, biomarkers, clinical research and external innovation, we are poised for continued leadership and growth, bringing transformational medicines to patients and healthcare professionals around the world.

    Visit the Janssen Website
    Our vision is a world free from immune diseases. To achieve this, we will translate internal and external science to deliver products that treat, cure, intercept, and prevent immune-mediated diseases.
    — Newman Yeilding, M.D., Global Therapeutic Head, Janssen Immunology
  • Cardiovascular & Metabolic Disease
    Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases.

    Every year, more than 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases with the goal to eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We continue to seek and develop the next generation of transformational cardiovascular & metabolic therapies.

    Visit the Janssen Website
    Our deep scientific expertise and demonstrated clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases.
    — James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism
  • Pulmonary Hypertension
    For almost two decades, Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson, has been working to fundamentally change the way pulmonary arterial hypertension (PAH) is treated.

    Pulmonary hypertension refers to high blood vessel pressure in the lungs, and PAH is a rare, progressive form of this often-debilitating condition. While the disease affects more women than men, it can also develop in children of any age and across all ethnicities. About 15 people out of every million are affected by PAH. Our understanding of the complex pathways and molecular mechanisms of PAH has enabled us to develop tailored medicines to improve patient outcomes and make a difference for people around the world living with this disorder.

We are actively developing treatments for our patients in six important therapeutic areas, including Infectious Diseases & Vaccines, Neuroscience, and Oncology.
  • Infectious Diseases & Vaccines
    We strive to discover and develop novel therapeutics and vaccines to treat and cure infectious diseases worldwide, improving treatment outcomes and patients’ lives.

    Our vision is to advance human health by helping to achieve a world free of life-threatening infectious diseases. We will do this by discovering and developing transformational therapies and vaccines that prevent, treat and cure some of the world’s most life-threatening infectious diseases such as HIV, viral hepatitis, respiratory syncytial virus, influenza and Ebola.

    Visit the Janssen Website
    18 of our prescription medicines are on the World Health Organization’s list of Essential Medications.
  • Neuroscience
    Our mission is to reduce the burden, disability and devastation caused by serious neuro psychiatric diseases and pain conditions.

    The research priorities of our Neuroscience Therapeutic Area include Alzheimer’s Disease, Mood Disorders and Schizophrenia. Across neuroscience, our researchers are exploring the emerging science of synaptic plasticity and cellular resilience, with an emphasis on developing novel therapeutics for the treatment of severe mood disorders and neurodegenerative dementias. We are deeply committed to patients with these conditions and to the healthcare professionals and loved ones who care for them.

    Visit the Janssen Website
    Janssen is leading efforts to discover and develop innovative therapeutic solutions for people with brain disorders and to eliminate the social stigma about these diseases.
    — Husseini Manji, M.D., F.R.C.P.C., Global Therapeutic Area Head, Neuroscience
  • Oncology
    We envision a world where cancer is a preventable chronic or curable disease. To get there, we’re focused on developing solutions that prolong and improve patient lives.

    Cancer claims millions of lives every year and the number continues to rise. We aim to transform cancer to a preventable or curable disease by delivering diagnostic and therapeutic solutions that prolong and improve patients’ lives. We are committed to delivering targeted therapies to fight the devastation of cancer.

    Visit the Janssen Website
    We envision a world where cancer is a preventable or curable disease. To get there, we're focusing on transformational science that will allow patients to live longer and better lives.
    — Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology

Pharmaceutical Products: 130 Years of Innovation

The First Family Planning Product

Ortho-Gynol was introduced in 1931 as the first prescription family planning product from the Ortho Products operating unit. This pioneering contraceptive gel was based on the need for trusted family planning products.

A New Standard for Treating Schizophrenia

HALDOL? (haloperidol) was discovered by Janssen Pharmaceutica, N.V. in 1960. Patients taking HALDOL? could be treated at home instead of in an institution. It became the gold standard for treating schizophrenia for more than 25 years.

Birth Control Options

Ortho Pharmaceutical introduces the second oral contraceptive available in the United States (Ortho-Novum 10 and Ortho-Novum 2, produced by Syntex).

Tackling Rh Hemolytic Disease

Ortho Diagnostic Systems introduces RhoGAM Rho(D) immune globulin, the first medication developed to prevent Rh hemolytic disease of the newborn.

Making Vaccines Affordable for the Whole World

We introduced the PER.C6 human cell line technology that enables faster and most cost effective discovery, development and production of a range of potentially transformational vaccines and monoclonal antibodies.

Treating Anemia

PROCRIT?, approved by the U.S. FDA for use in 1989, is a prescription medicine used to treat certain types of anemia.

A New Treatment for Auto-immune Conditions

Centocor, now part of Janssen Biotech Inc., introduces REMICADE?, a prescription medication used to treat many auto-immune conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and plaque psoriasis.

Hope for Preventing Ebola

AdVac? technology, based on the development and production of adenovirus vectors is introduced. It can be used with PER.C6? technology to develop recombinant vaccines against life-threatening infectious diseases such as Ebola.

Johnson & Johnson Creates The Dr. Paul Janssen Award for Biomedical Research

Established in celebration of the legacy of “Dr. Paul” and in recognition of current researchers demonstrating a similar spirit, the Dr. Paul Janssen Award was first presented in 2006.

Prostate Cancer Options

ZYTIGA?, a prescription medication used in combination with prednisone to treat men with metastatic castration-resistant prostate cancer, is introduced.

DARZALEX? Launches

DARZALEX? (daratumumab) injection for intravenous infusion is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.

WHO Essential Medicines

Eleven Janssen products are on the WHO Model List of Essential Medicines.













This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.